Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Safety and Immunogenicity of An Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam

medRxiv(2022)10.1101/2022.02.01.22270253Source: DataRank Database

Safety and Immunogenicity of An Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam is a research paper published in medRxiv (2022). On theSindex it has a DataRank of 0. It has been cited 3 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access3 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)OA: greenTopics (52)IDs (PubMed, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (33)

Vũ Đình Thiểm ORCID,Ha Hai Vu,Van Thanh Ta,Anh Thi Van Pham ORCID,Mai Thị Ngọc Đặng

Live enrichment

PubMed:19162232 OpenAlex:https://openalex.org/W4210787958

National Institutes of Health

Grant: 3R01AI145870-02S1

Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection

National Institutes of Health

Grant: 5P01AI097092-04

Monoclonal Antibody Technology Core

greenLicense: cc-by-nd

repositoryhttps://www.medrxiv.org/content/medrxiv/early/2022/02/05/2022.02.01.22270253.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1101/2022.02.01.22270253

repositoryhttps://doi.org/10.1101/2022.02.01.22270253

Europe_PMChttps://europepmc.org/article/PPR/PPR450829

Fields of Study

SARS-CoV-2 and COVID-19 ResearchViral gastroenteritis research and epidemiologyAnimal Virus Infections Studies0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

MedicineInterim analysisPlaceboVaccinationImmunogenicityVirologyAdverse effectRandomized controlled trialVirusInternal medicineImmunologyAntibodyPathologyAlternative medicineEpidemiologyFOS: Health sciencesAntibodies, ViralAgricultural and Biological SciencesImmunogenicity, VaccineParamyxovirus Infections and EpidemiologyVaccinesLife SciencesMiddle AgedInfectious DiseasesVietnamSpike Glycoprotein, CoronavirusAdultCOVID-19 VaccinesAdolescentNewcastle disease virusCoronavirus Disease 2019 ResearchArticleYoung AdultAdjuvants, ImmunologicDouble-Blind MethodHealth SciencesHumansViral Diseases in Livestock and PoultryCOVID-19 SerotherapySARS-CoV-2FOS: Clinical medicineImmunization, PassiveCOVID-19Antibodies, NeutralizingVaccines, InactivatedAnimal Science and Zoology

Sustainable Development Goals

SDG 3: 3. Good health

Safety and Immunogenicity of An Egg-Based Inactivated Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomized, Placebo-Controlled, Phase 1/2 Trial in Vietnam

FAIR Checklist

Authors (33)

Funding (2 grants)

Open Access

Topics

Annotations (Europe PMC)